Radioprotection in mice following oral administration of WR-1065/PLGA nanoparticles

International Journal of Radiation Biology

Volumn 84, Issue 11, 2008, Pages 900-908

  Pamujula, Sarala ^a   Kishore, Vimal ^a,c   Rider, Barbara ^b   Agrawal, Krishna C ^b   Mandal, Tarun K ^a  

^a XAVIER UNIVERSITY OF LOUISIANA   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Bynum and Sons Inc

Author keywords

Amifostine; Oral delivery; PLGA nanoparticles; Radioprotection; WR 1065

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; NANOPARTICLE; POLYGLACTIN;

ANIMAL EXPERIMENT; ARTICLE; BONE MARROW SUPPRESSION; CHROMATOGRAPHY; CONTROLLED STUDY; DOSE RESPONSE; DRUG FORMULATION; ENCAPSULATION; GAMMA IRRADIATION; INTESTINE INJURY; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIATION PROTECTION; SPRAY DRYING; SURVIVAL; WHOLE BODY RADIATION;

ADMINISTRATION, ORAL; ANIMALS; BONE MARROW; CELL SURVIVAL; JEJUNUM; MALE; MERCAPTOETHYLAMINES; MICE; NANOPARTICLES; POLYGLACTIN 910; RADIATION-PROTECTIVE AGENTS; STEM CELLS; SURVIVAL RATE;

MUS;

EID: 57049104679     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.1080/09553000802460198     Document Type: Article

References (27)

1. Andreassen CN, Grau C, Lindegaard JC. 2003. Chemical radioprotection: A critical review of amifostine as a cytoprotector in radiotherapy. Seminars in Radiation Oncology 13:62-72.
2. Batista CKLP, Mota JMSC, Souza MLP, Leitao BTA, De Souza MHLP, Brito GAC, Cunha FQ, Ribeiro RA. 2007. Amifostine and glutathione prevent ifosfamide- and acrolein-induced hemorrhagic cystitis. Cancer Chemotherapy and Pharmacology 59:71-77.
3. Belkacemi Y, Rat P, Piel G, Christen MO, Touboul E, Warnet JM. 2001. Lens epithelial cell protection by aminothiol WR-1065 and anetholedithiolethione from ionizing radiation. International Journal of Cancer 96(Suppl.):15-26.
4. Ben-Josef E, Han S, Tobi M, Vargas BJ, Stamos B, Kelly L, Priggar S, Kaplan I. 2002. Intrarectal application of amifostine for the prevention of radiation-induced rectal injury. Seminars in Radiation Oncology 12:81-85.
5. Beutel J, Schroder C, von Hof K, Rades D, Kosmehl H, Wedel T, Sieg P, Geerling G, Hakim SG. 2007. Pharmacological prevention of radiation-induced dry eye-an experimental study in a rabbit model. Graefes Archive for Clinical and Experimental Ophthalmology 245:1347-1355.
6. Bonner SH, Shaw LM. 2002. New dosing regimen for amifostine: A pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion. Journal of Clinical Pharmacology 42:166-174.
7. Cassatt DR, Fazenbaker CA, Bachy CM, Kifle G, McCarthy MP. 2005. Amifostine (ETHYOL) protects rats from mucositis resulting from fractionated or hyperfractionated radiation exposure. International Journal of Radiation Oncology, Biology, Physics 61(3):901-907.
8. Evans HH, Evans TE, Horng MF. 2002. Antimutagenecity of WR-1065 in L5178Y cells exposed to accelerated (56) Fe ions. Radiation Research 158(1):110-114.
9. Fatome M, Courteille F, Laval JD, Roman V. 1987. Radioprotective activity of ethylcellulose microspheres containing WR 2721, after oral administration. International Journal of Radiation Biology and Related Studies in Physics, Chemistry, and Medicine 52:21-29.
10. Ganz T. 2000. Paneth cells-guardians of the gut cell. Nature Immunology 1:99-100.
11. Geary RS, Swynnerton NF, Timmons SF, Mangold DJ. 1991a. Characterization of ethiofos absorption in the rat small intestine. Biopharmaceutics & Drug Disposition 12:261-274.
12. Geary RS, Swynnerton NF, Timmons SF, Mangold DJ. 1991b. Characterization of WR-1065 absorption in the rat small intestine. Biopharmaceutics & Drug Disposition 12:275-284.
13. Gogu SR, Beckman BS, Rangan SRS, Agrawal KC. 1989. A significant increase in therapeutic effect of zidvudine in the presence of vitamin E. Biochemical and Biophysical Research Communications 165:401-407.
14. Harari Y, Grossie VB, Castro A. 1996. Nutritional support for adaptation to radiation-induced suppression of mucosal immunity in the intestine of the rat. Radiation Research 145:754-761.
15. Hatoum GF, Nevaldine B, Bhavsar T, Phung Q, Hahn PJ. 2004. WR-1065, the active form of amifostine, protects HL-60 cells but not peripheral blood mononuclear cells from radiation and etoposide-induced apoptosis. International Journal of Radiation Oncology, Biology, Physics 59:844-851.
16. Jin JO, Lehmann J, Taxy J, Huo D, Stokle M, Vogelzang NJ, Steinberg G, Stadler WM. 2006. Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer. Clinical Genitourinary Cancer 5:150-154.
17. Kouvaris JR, Kouloulias VE, Vlahos LJ. 2007. Amifostine: The first selective-target and broad-spectrum radioprotector. The Oncologist 12:738-747.
18. Mangold DJ, Huelle BK, Miller MA, Geary RS, Sanchez-Barona DOT, Swynnerton NF, Fleckenstein L, Ludden TM. 1990. Pharmacokinetics and disposition of WR-1065 in the rhesus monkey. Drug Metabolism and Disposition 18:281-287.
19. Mell LK, Malik R, Komaki R, Movsas B, Swann RS, Langer C, Antonadou D, Koukourakis M, Mundt AJ. 2007. Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: A meta-analysis. International Journal of Radiation Oncology, Biology, Physics 68:111-118.
20. Mota JMSC, Soares PMG, Menezes AAJ, Lemos HP, Cunha FQ, Brito GAC, Ribeiro RA, De Souza MHLP. 2007. Amifostine (WR-2721) prevents indomethacin-induced gastric damage in rats: Role of non-protein sulfhydryl groups and leukocyte adherence. Digestive Diseases and Sciences 52:119-125.
21. Pamujula S, Graves R, Kishore V, Mandal TK. 2004. Preparation and in vitro characterization of amifostine biodegradable microcapsules. European Journal of Pharmaceutics and Biopharmaceutics 57:213-221.
22. Pamujula S, Kishore V, Rider B, Fermin C, Graves R, Agrawal K, Mandal TK. 2005. Radioprotection in mice following oral delivery of amifostine nanoparticles. International Journal of Radiation Biology 81:251-257.
23. Praetorius N, Mandal TK. 2008. Alternate delivery route for amifostine as a radio-/chemo-protecting agent. Journal of Pharmacy and Pharmacology 60:809-815.
24. Singh AK, Menard C, Guion P, Simone NL, Smith S, Crouse NS, Godette DJ, Cooley-Zgela T, Sciuto LC, Coleman J, Pinto P, Albert PS, Camphausen K, Coleman CN. 2006. Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: A pilot study. International Journal of Radiation Oncology, Biology, Physics 65:1008-1013.
25. Srinivasan V, Pendergrass JA, Kumar KS, Landauer MR, Seed TM. 2002. Radioprotection, pharmacokinetic and behavioral studies in mouse implanted with biodegradable drug (amifostine) pellets. International Journal of Radiation Biology 78:535-543.
26. Uma DP, Veena K. 1993. Mouse jejunal response to multifraction treatments with gamma radiation and chemicals. Strahlentherapie und Onkologie 169:196-201.
27. Weiss JF, Landauer MR, Hogan JB, Gunter-Smith PJ, Benson KA, Neta R, Hanson WR. 1997. Modification of radiation-induced gastrointestinal and hematopoietic injury in mice by combinations of agents: Effects of indomethacin and caffeine. Advances in Experimental Biology 400B:865-872.